Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status

Journal of the National Cancer Institute

Volumn 98, Issue 4, 2006, Pages 285-288

  Menin, Chiara ^a   Scaini, Maria Chiara ^c   De Salvo, Gian Luca ^b   Biscuola, Martina ^b   Quaggio, Monica ^c   Esposito, Giovanni ^b   Belluco, Claudio ^c   Montagna, Marco ^a   Agata, Simona ^c   D'Andrea, Emma ^c   Nitti, Donato ^c   Amadori, Alberto ^c   Bertorelle, Roberta ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENES, P53; GENOTYPE; GLYCINE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MDM2; THREONINE;

EID: 33144460815     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj054     Document Type: Article

References (16)

1. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004; 4: 769-80.
2. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology 2001; 121: 282-301.
3. de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, de Vries EG, Sijmons RH, et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2002;11:1332-52.
4. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
5. Bears OH, Henson DE, Hutter RV, Kennedy BJ, editors. American Joint Committee on Cancer (AJCC). Manual of staging of cancer. 4th ed. Philadelphia (PA): Lippincott; 1992.
6. Bertorelle R, Esposito G, Del Mistro A, Belluco C, Nitti D, Lise M, et al. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol 1995; 19: 463-71.
7. Hollander Myles, Wolfe DA. Nonparametric statistical methods. New York (NY): John Wiley & Sons; 1973. p. 75-82.
8. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
9. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26: 3453-9.
10. Abdel-Fattah G, Yoffe B, Krishnan B, Khaoustov V, Itani K. MDM2/p53 protein expression in the development of colorectal adenocarcinoma. J Gastrointest Surg 2000; 4: 109-14.
11. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, et al. A chromatin associated and transcriptionally inactive p53-MDM2 complex occurs in MDM2 SNP 309 homozygous cells. J Biol Chem 2005; 280: 26776-87.
12. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13: 49-58.
13. Ganguli G, Wasylyk B. p53-independent functions of MDM2. Mol Cancer Res 2003; 1: 1027-35.
14. Broll R, Stark A, Windhovel U, Best R, Strik MW, Schimmelpenning H, et al. Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas. Eur J Cancer 1999; 35: 1083-8.
15. Tachibana M, Kawamata H, Fujimori T, Omotehara F, Horiuchi H, Ohkura Y, et al. Dysfunction of p53 pathway in human colorectal cancer: Analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2. Int J Oncol 2004; 25: 913-20.
16. Varley JM, Thorncroft M, McGown G, Appleby J, Kelsey AM, Tricker KJ, et al. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 1997; 14: 865-71.